Grail (NASDAQ:GRAL – Get Free Report) announced its quarterly earnings data on Thursday. The company reported ($1.86) EPS for the quarter, beating the consensus estimate of ($4.41) by $2.55, Zacks reports.
Grail Price Performance
Shares of GRAL traded down $4.84 during mid-day trading on Thursday, hitting $47.76. 1,508,252 shares of the company’s stock traded hands, compared to its average volume of 1,453,586. The business’s 50-day moving average price is $25.78 and its 200-day moving average price is $18.86. Grail has a 1 year low of $12.33 and a 1 year high of $63.99.
Analysts Set New Price Targets
Several brokerages recently weighed in on GRAL. Morgan Stanley initiated coverage on Grail in a report on Wednesday, November 27th. They set an “equal weight” rating and a $16.00 target price for the company. Wolfe Research initiated coverage on shares of Grail in a report on Friday, November 15th. They set a “peer perform” rating for the company.
About Grail
GRAIL, Inc is a healthcare company. It engages in the development of a technology for early detection of cancer. The company was founded by Jeffrey T. Huber, William H. Rastetter, and Mostafa Ronaghi on September 11, 2015 and is headquartered in Menlo Park, CA.
Read More
- Five stocks we like better than Grail
- Breakout Stocks: What They Are and How to Identify Them
- Ray Dalio’s Bridgewater Loaded Up on These Stocks in Q4 2024
- How the NYSE and NASDAQ are Different, Why That Matters to Investors
- Walmart Faces Tariff Headwinds, Consumer Trends Remain Positive
- How to Use the MarketBeat Stock Screener
- Tesla: 2 Reasons to Buy, 1 Reason to Run
Receive News & Ratings for Grail Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Grail and related companies with MarketBeat.com's FREE daily email newsletter.
